In the June/July 2015 issue of the American Gastroenterological Association’s magazine, “Perspectives,” celiac disease experts Sonia Kupfer, MD and Daniel Leffler, MD, MS provide an overview of the landmark GREAT3 Workshop and what it means for people with the genetic autoimmune disease.
On March 31, 2015, celiac disease history was made at the U.S. Food and Drug Administration’s (FDA) GREAT3 Workshop. The Gastroenterology and Regulatory Endpoints and Advancement of Therapeutics (GREAT3) Workshop brought together leading experts from the field to identify what success looks like for developing pharmaceutical therapies for celiac disease.
Representing the patient’s voice at this landmark meeting was National Foundation for Celiac Awareness (NFCA) President and CEO Alice Bast. In addition to the research experts who provided an overview of the celiac disease landscape, Bast added the patient’s experience and what it’s like to manage this serious genetic autoimmune disease each and every day.
NFCA was proud to work with the North American Society for the Study of Celiac Disease (NASSCD) and the Celiac Disease Foundation (CDF) to financially support the GREAT3 workshop.
A full overview of this historic meeting was written by Sonia Kupfer, MD, Assistant Professor of Medicine, Co-Director, Comprehensive Cancer Risk and Prevention Clinic, The University of Chicago Medicine and Daniel Leffler, MD, MS,Director of Clinical Research at the Celiac Center at Beth Israel Deaconess Medical Center (BIDMC) and NFCA Scientific/Medical Advisory Council Member.